Syndax Pharmaceuticals.
business
- Reports this week
- 1
- Active events
- 1
- Connections
- 36
What's happening
Active this week
Earlier this month
-
Analysts set price targets for Syndax Pharmaceuticals stock on September 1, 2025.Well supported3 reports
-
Shares of Syndax Pharmaceuticals were traded on the Nasdaq stock exchange on August 12, 2026.Some support3 reports1 development inside
-
Syndax Pharmaceuticals' share price dropped following a clinical trial failure.Some support1 report
-
Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.Well supported5 reports
One to three months ago
Gone quiet
No new reports in 90+ days-
Syndax Pharmaceuticals confirms Michael Metzger as CEO and Botwood as Chief Medical Officer.Some support2 reports
-
CEO Michael Metzger sold shares of Syndax Pharmaceuticals stock.Some support1 report
-
On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.Speculative1 report1 development inside
-
Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Syndax Pharmaceuticals.Some support1 report
-
FDA granted Priority Review for Syndax's sNDA on June 25, 2025.Speculative2 reports
-
Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.Some support7 reports1 development inside
-
Syndax Pharmaceuticals' stock price moved following changes in earnings estimates, prompting institutional investors to calculate fair value.Some support1 report
-
FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Syndax Pharmaceuticals this week
News at the entities that move Syndax Pharmaceuticals most-
FDA StructuralBDR Pharmaceuticals filed a lawsuit challenging FDA decisions related to Phathom Pharmaceuticals' drug applications.Moves Syndax Pharmaceuticals
-
Incyte OperationalIncyte is scheduled to present research data at the European Society for Medical Oncology (ESMO) congress in Madrid.Moves Syndax Pharmaceuticals
-
Bank of America OperationalSEC disclosure tracks institutional investment activity involving Bank of America and Avery Dennison.Moves Syndax Pharmaceuticals
-
Nasdaq StructuralTraders magazine reported on the technology utilized within the Wall Street financial market.Moves Syndax Pharmaceuticals
-
AbbVie OperationalAbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.Moves Syndax Pharmaceuticals
-
Stockholm Shared contextHaryana seeks Stockholm's city model for urban issues, with Nayab Singh Saini visiting Stockholm to form a partnership.Moves Syndax Pharmaceuticals
Connections
The 15 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Incyte Operational
Syndax and Incyte maintain an exclusive worldwide co-development and co-commercialization partnership for the drug Niktimvo.
-
FDA Structural
The FDA formally regulates Syndax Pharmaceuticals, reviewing and approving its therapeutic pipeline.
-
Nasdaq Structural
Syndax Pharmaceuticals is a publicly listed company whose shares are traded on the Nasdaq stock exchange.
-
Botwood Structural
Botwood serves as the chief medical officer for Syndax Pharmaceuticals.
-
Michael Metzger Structural
Michael Metzger serves as the Chief Executive Officer of Syndax Pharmaceuticals.
-
AbbVie Operational
The two companies are actively competing against each other within the specialized healthcare and biopharma market.
-
Bank of America Operational
Bank of America provides market assessments and commentary regarding the stock performance of Syndax Pharmaceuticals.
-
Stockholm Shared context
Syndax Pharmaceuticals is located in Stockholm, where it presented data at EHA Congress.
Show all 15 connections
-
Milan Shared context
Syndax Pharmaceuticals presents scientific data at the EHA Congress held in Milan.
-
LinkedIn Mentioned together
Syndax Pharmaceuticals utilizes LinkedIn as a professional platform to disseminate company news and updates.
-
New York Shared context
Syndax Pharmaceuticals is located in New York, establishing a geographical context for the company.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and financial information regarding Syndax Pharmaceuticals.
-
New York City Shared context
Syndax Pharmaceuticals is reported to be operating within the context of New York City.
-
Italy Shared context
Syndax Pharmaceuticals operates within the geographical context of Italy for scientific congresses.
-
New York Shared context
Syndax Pharmaceuticals operates within the context of New York, a major market backdrop.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
1 eventShow 2 earlier months
July 2026
2 eventsJune 2026
9 events- Syndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.
- Analysts set price targets for Syndax Pharmaceuticals stock on September 1, 2025.
- Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.
- On June 25, 2025, the FDA approved revumenib for acute leukemia, and data was presented at the EHA Congress in Milan.
- Trump's pledge to unleash oil and gas benefits US stocks, specifically impacting Syndax Pharmaceuticals.
- FDA granted Priority Review for Syndax's sNDA on June 25, 2025.
- Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
- Syndax Pharmaceuticals' stock price moved following changes in earnings estimates, prompting institutional investors to calculate fair value.
- FDA approval of Revuforj is key catalyst for Syndax Pharmaceuticals.